Randomized Study of Haploidentical Hct and Subsequent Donor nk Cell Infusion in High-risk AML and MDS

PHASE2TerminatedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

June 30, 2019

Study Completion Date

June 30, 2019

Conditions
Acute Myelogenous Leukemia
Interventions
BIOLOGICAL

allogeneic, donor-derived NK cells

"Patients in the study arm will receive donor NK cell infusion around days 13 and 20. A permissible range of infusion time will be +/- 3 days.~For DNKI to be given on day 13 (DNKI-1), the cell dose is 1-2 x108/kg or about the half of amount generated. For DNKI to be given on day 20 (DNKI-2), the cell dose is up to 5x108/kg.~Avil 1 ampoule will be given intravenously 30 minutes prior to each NK cell infusions."

Trial Locations (1)

Unknown

Asan Medical Center, Seoul

Sponsors
All Listed Sponsors
lead

Asan Medical Center

OTHER